Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:7 Number:601 ISSN#:2563-5476
ACE Report #5081
Ace Report Cover Osteoarthritis

Tocilizumab more effective in reducing rheumatoid arthritis symptoms than adalimumab

How to Cite

OrthoEvidence. Tocilizumab more effective in reducing rheumatoid arthritis symptoms than adalimumab. ACE Report. 2013;2(7):601. Available from: https://myorthoevidence.com/AceReport/Report/5081

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Lancet. 2013 May 4;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0. Epub 2013 Mar 18

Contributing Authors: C Gabay P Emery R van Vollenhoven A Dikranian R Alten K Pavelka M Klearman D Musselman S Agarwal J Green A Kavanaugh ADACTA Study Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


326 patients with severe rheumatoid arthritis, with whom methotrexate was deemed inappropriate, were randomized to receive tocilizumab intravenously every 4 weeks plus a placebo subcutaneously every 2 weeks for 24 weeks or adalimumab subcutaneously every 2 weeks plus a placebo intravenously every 4 weeks for 24 weeks, in order to compare the safety and efficacy between the two drugs. After the 24 ...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.